Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8148780 | 0.98 | MAPT (0.42) | ALDH1A1MAPTITGA4NPSR1MAPK1 | |
| SCHEMBL12455851 | 0.93 | MAPT (0.37) | ALDH1A1MAPTITGA4NPSR1MAPK1 | |
| SCHEMBL9458211 | 0.93 | ALDH1A1 (0.37) | ALDH1A1MAPTITGA4NPSR1MAPK1 | |
| SCHEMBL731545 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MAPTITGA4SMN1; SMN2CHRNB2 | |
| SCHEMBL751058 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MAPTITGA4SMN1; SMN2CHRNB2 | |
| SCHEMBL12455857 | 0.82 | ALDH1A1 (0.40) | ALDH1A1MAPTITGA4CHRNB2CHRNA4 | |
| SCHEMBL16795845 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTITGA4NPSR1MAPK1 | |
| SCHEMBL16808513 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTITGA4NPSR1MAPK1 | |
| SCHEMBL27085627 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTITGA4NPSR1MAPK1 | |
| SCHEMBL17093406 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTITGA4NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404088-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2007139749-A2 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | NFKBIA, NFKB1, NFE2L2 | ALDH1A1 431/4885MAPT 4445/4885ITGA4 3458/4885 |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | NFKBIA, NFKB1, NFE2L2 | ALDH1A1 431/4885MAPT 4445/4885ITGA4 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.